Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersMedical Oncology Physician in Houston, TX
NPI: 1043270416Primary Employer
Physicians Referral Service
mdanderson.org
HQ Phone
Get M.D. Frank's Phone Numberphone_androidMobile
Get M.D. Frank's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardLA State Medical License
TX State Medical License
GA State Medical License
FL State Medical License
2021
LA State Medical License
2011
TX State Medical License
1980 - 2025
TX State Medical License
1989 - 2025
OK State Medical License
2020 - 2021
GA State Medical License
2013 - 2017
LA State Medical License
2010 - 2017
WI State Medical License
1989 - 2005
University of Wisconsin Hospitals and Clinics
Fellowship • Medical Oncology
1991 - 1994
Residency • Internal Medicine
1988 - 1991
Texas A&M College of Medicine - Bryan
medicine.tamu.edu
Medical School
Until 1988
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 43 | 52 |
| 2 | 99213Established patient office or other outpatient visit, typically 15 minutes | 38 | 54 |
| 3 | 99214Established patient office or other outpatient visit, 30-39 minutes | 21 | 21 |
| 4 | 99205New patient office or other outpatient visit, typically 60 minutes | 13 | 13 |
Patient Reported Outcomes (PROs) as Part of Value-Based Care Can Shape Therapy Guidelines: Impact on Emerging Targeted Agents and Immunotherapy Protocols in Resource-Limited Regions.
Authors: Frank Mott
Publication Date: 2016-10-25
'Brain metastases in N2-positive non-small-cell lung cancer: Implications for
Authors: Teresa Boyle, Frank E. Mott, Alex Ehsan, Mollit Bansal
Publication Date: 2008-07
Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations.
Authors: John Heymach, Vincent Lam
Publication Date: 2021-08-19
Lead Sponsor: Genocea Biosciences, Inc.
Intervention / Treatment: DRUG: Cyclophosphamide, DRUG: Fludarabine, DRUG: IL-2, BIOLOGICAL: GEN-011
Lead Sponsor: Genocea Biosciences, Inc.
Intervention / Treatment: DRUG: Nivolumab, DRUG: Pembrolizumab, BIOLOGICAL: GEN-009 Adjuvanted Vaccine